Armata Pharmaceuticals Welcomes Dr. Daniel B. Gilmer to Its Board of Directors

On April 24, 2026, Armata Pharmaceuticals, Inc., a biotechnology company at the forefront of developing bacteriophage therapies for antibiotic-resistant infections, proudly announced the appointment of Dr. Daniel B. Gilmer to its Board of Directors. A notable figure in the field, Dr. Gilmer brings a wealth of experience and expertise that will help steer Armata towards achieving its ambitious clinical and commercial objectives.

Background of Dr. Daniel B. Gilmer

Dr. Gilmer has a distinguished career as a healthcare executive, prominently serving as the Senior Director of the Commercial Quality U.S. Team at Pfizer since February 2025. His role at Pfizer has encompassed critical oversight of quality and promotional activities across a portfolio of more than 50 brands. Moreover, Dr. Gilmer's extensive background in scientific discovery and commercial strategy makes him an invaluable asset to Armata.

Before his tenure at Pfizer, Dr. Gilmer played a key role in advancing antiviral therapies, successfully leading the U.S. launch of PAXLOVID™, which received New Drug Approval from the FDA. This significant achievement highlights his capabilities within the biopharmaceutical landscape, particularly in launching groundbreaking therapies that address pressing healthcare challenges.

At Armata, Dr. Gilmer's contributions will focus on utilizing innovative strategies to enhance patient access and effectively combat antimicrobial resistance. His deep understanding of the complexities associated with diagnostics and therapy development will provide invaluable insight as Armata continues to advance its promising bacteriophage pipeline.

The Importance of Bacteriophage Therapy

With the increasing threat of antibiotic-resistant bacteria, Armata Pharmaceuticals is pioneering the development of high-purity, pathogen-specific bacteriophage therapeutics. These novel treatments represent a significant advancement in addressing stubborn bacterial infections that traditional antibiotics can no longer effectively manage. Dr. Gilmer's experience will be crucial in navigating the challenges associated with bringing these innovative therapies to market.

As outlined by Robin C. Kramer, Chair of Armata's Board of Directors, Dr. Gilmer’s track record of advancing first-in-class anti-infective candidates underscores his commitment to improving patient outcomes. Armata is positioned to leverage his expertise as it progresses toward commercialization of its unique bacteriophage-based therapies.

Vision for the Future

In his remarks following the announcement, Dr. Gilmer expressed excitement about his role, noting that he is eager to work with the Board and the leadership team at Armata to further the Company’s objectives. He emphasized the growing global crisis of antibiotic resistance and how Armata’s commitment to addressing this issue aligns with his professional mission. He aims to utilize his experience and strategic mindset to enhance the impact of Armata’s therapies on the healthcare landscape.

Conclusion

The appointment of Dr. Daniel B. Gilmer to Armata Pharmaceuticals’ Board of Directors is a strategic move designed to capitalize on his extensive background in biopharmaceuticals and commercial strategy. As the battle against antibiotic-resistant infections intensifies, Dr. Gilmer's insight will play a pivotal role in driving Armata's innovative solutions to market. With plans for further advancement of its bacteriophage pipeline, Armata is poised to make significant strides in addressing this urgent public health crisis. With industry leaders like Dr. Gilmer on board, the future looks promising for Armata Pharmaceuticals and the patients who stand to benefit from its groundbreaking therapies.